| Literature DB >> 23927773 |
Ke Chen1, Xiao-Wu Xu, Yi-Ping Mou, Yu Pan, Yu-Cheng Zhou, Ren-Chao Zhang, Di Wu.
Abstract
BACKGROUND: The use of laparoscopic gastrectomy (LG) in advanced gastric cancer (AGC) remains a controversial topic, mainly because of doubts about its oncologic validity. This study is a systematic review and meta-analysis of the available evidence.Entities:
Mesh:
Year: 2013 PMID: 23927773 PMCID: PMC3750547 DOI: 10.1186/1477-7819-11-182
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Figure 1Flow chart of literature search strategies.
Characteristics of included studies
| Huscher | Italy | RCT | 2005 | 1992-1996 | 30 | 29 | D1, D2 | DG | B-II, R-Y | NR | NR | 3* |
| Hur | Korea | Retrospective | 2008 | 2004-2007 | 26 | 25 | D2 | DG | B-I, B-II | 76.9 | 68 | 8 |
| Du XH | China | Retrospective | 2009 | 2004-2008 | 78 | 90 | D2 | DG | B-I, B-II | NR | NR | 7 |
| Hwang | Korea | Retrospective | 2009 | 2004-2007 | 45 | 83 | D1 + | DG | B-I, B-II | 93.2 | 89.0 | 7 |
| Du J | China | Retrospective | 2010 | 2005-2009 | 82 | 94 | D2 | TG | R-Y | 100 | 100 | 8 |
| Cai | China | RCT | 2011 | 2008-2009 | 49 | 47 | D2 | DG, PG, TG | B-I, B-II, R-Y | 100 | 100 | 2* |
| Scatizzi | Italy | Retrospective | 2011 | 2006-2009 | 30 | 30 | D2 | DG | R-Y | NR | NR | 8 |
| Shuang | China | Retrospective | 2011 | 2005-2007 | 35 | 35 | D2 | DG | B-II | NR | NR | 8 |
| Zhao | China | Retrospective | 2011 | 2004-2009 | 346 | 313 | D1 + | DG | B-I, B-II | 93.1 | 91.7 | 9 |
| Chen | China | Retrospective | 2012 | 2008-2010 | 224 | 112 | D2 | DG, TG | B-I, B-II, R-Y | NR | NR | 8 |
| Chun | Korea | Retrospective | 2012 | 2004-2009 | 52 | 67 | D2 | DG | B-I, B-II, R-Y | NR | NR | 9 |
| Kim | Korea | Retrospective | 2012 | 1999-2007 | 88 | 88 | D2 | DG, TG | B-I, B-II, R-Y | NR | NR | 9 |
| Moisan | Chile | Retrospective | 2012 | 2005-2010 | 31 | 31 | D1 + α/β, D2 | DG, TG | B-II, R-Y | 19.4 | 22.6 | 8 |
| Siani | Italy | Retrospective | 2012 | 2003-2009 | 25 | 25 | D1 + α/β, D2 | TG | R-Y | NR | NR | 9 |
| Shinohara | Japan | Retrospective | 2013 | 1998-2008 | 186 | 123 | D2 | DG, PG, TG | B-I, R-Y | 61.3 | 58.5 | 9 |
Abbreviations: RCT Randomized controlled trial, LG Laparoscopic gastrectomy, OG Open gastrectomy, DG Distal gastrectomy, PG Proximal gastrectomy, TG Total gastrectomy, B-I Billroth-I, B-II Billroth-II, R-Y Roux-en-Y, NR Not reported. *Jadad scores.
Figure 2Meta-analysis of the pooled data: number of retrieved lymph nodes.
Pooled short-term outcomes of meta-analysis
| Operating time (min) | 15 | 1327 | 1192 | <0.001, 93% | WMD = 48.67 | 34.09−63.06 | <0.001 |
| Blood loss (ml) | 12 | 1157 | 1007 | <0.001, 91% | WMD = −139.01 | −174.57− −103.44 | <0.001 |
| Retrieved lymph nodes | 15 | 1327 | 1192 | 0.26, 17% | WMD = −0.07 | −1.03−0.89 | 0.88 |
| Proximal margin (cm) | 6 | 588 | 607 | 0.27, 21% | WMD = −0.26 | −0.54−0.01 | 0.06 |
| Distal margin (cm) | 4 | 517 | 499 | 0.86, 0% | WMD = 0.08 | −0.16−0.32 | 0.50 |
| Analgesics given (days) | 4 | 192 | 242 | <0.001, 89% | WMD = −1.57 | −2.40− −0.74 | <0.001 |
| Time to ambulation (days) | 6 | 913 | 755 | <0.001, 96% | WMD = −1.01 | −1.56− −0.45 | <0.001 |
| Time to first flatus (days) | 11 | 1045 | 974 | <0.001, 94% | WMD = −0.79 | −1.14− −0.44 | <0.001 |
| Time to oral intake (days) | 9 | 967 | 793 | <0.001, 87% | WMD = −1.06 | −1.63− −0.50 | <0.001 |
| Hospital stay (days) | 14 | 1238 | 1091 | <0.001, 84% | WMD = −3.11 | −4.13− −2.09 | <0.001 |
| Overall complications | 15 | 1327 | 1192 | 0.66, 0% | RR = 0.74 | 0.61−0.90 | 0.003 |
| Surgical complications | 15 | 1,327 | 1,192 | 0.56, 0% | RR = 0.73 | 0.58−0.92 | 0.007 |
| Medical complications | 12 | 868 | 754 | 0.40, 5% | RR = 0.65 | 0.41−1.02 | 0.06 |
| Mortality | 7 | 965 | 821 | 0.75, 0% | RR = 0.78 | 0.30−2.04 | 0.61 |
Abbreviations: WMD Weighted mean difference, RR Risk ratio.
Figure 3Meta-analysis of the pooled data: overall postoperative complications.
Figure 4Funnel plot of the overall postoperative complications.
Figure 5Meta-analysis of the pooled data: recurrences.
Systematic review of recurrence patterns and specific recurrent sites
| Hur | LG | 26 | 8 | 3 | 1 | 1 | | 2 | 1 |
| OG | 25 | 6 | | 5 | 1 | | | | |
| Du J | LG | 82 | 19 | 10 | | 5 | 4 | | |
| OG | 94 | 23 | 10 | | 7 | 4 | 2 | | |
| Chun* | LG | 52 | 4 | | 3 | 2 | | 1 | |
| OG | 67 | 7 | 1 | 5 | 1 | | 1 | 3 | |
| Kim* | LG | 88 | 13 | 2 | 4 | 6 | | 3 | 5 |
| OG | 88 | 15 | 2 | 4 | 4 | 3 | 2 | ||
Abbreviations: LR Local recurrence, LN Lymph node; *some patients had mixed tumor recurrence.
Figure 6Meta-analysis of the pooled data: survival rate. (A) 3y-DFS, (B) 5y-DFS, (C) 1y-OS, (D) 3y-OS and (E) 5y-OS. DFS, disease-free survival; OS, overall survival; y, year.
Systematic review of long-term survival outcomes
| Huscher | LG | 60 (2–88) | 11 | 5-y: 57.3 | 5-y: 58.9 |
| OG | 55 (7–90) | 10 | 5-y: 54.8 | 5-y: 55.7 | |
| Hur | LG | 29 (6–47) | 8 | 3-y: 71.4 | 3-y: 88.2 |
| OG | 6 | 3-y: 53.4 | 3-y: 77.2 | ||
| Du XH | LG | 25.2 (4–58) | 22 | NR | 3-y: 81.2 |
| OG | 31 | NR | 3-y: 74.7 | ||
| Hwang | LG | 23 (9–40) | 6 | NR | NR |
| OG | 23.5 (8–41) | 17 | NR | NR | |
| Du J | LAG | 25 (2–44) | 19 | NR | NR |
| OG | 23 | NR | NR | ||
| Cai | LG | 22.1 (4–36) | NR | NR | 3-y: 67.1 |
| OG | NR | NR | 3-y: 53.8 | ||
| Scatizzi | LG | 18 (2–37) | NR | NR | 3-y: 70.9 |
| OG | 18 (7–42) | NR | NR | 3-y: 56.8 | |
| Shuang | LG | 36.5 (23–50) | NR | NR | NR |
| OG | 38.5 (27–50) | NR | NR | NR | |
| Zhao | LG | 37 (6–72) | 147 | 5-y: 47 | 1-y: 87.2, 3-y: 57.2, 5-y: 50.3 |
| OG | 141 | 5-y: 46.8 | 1-y: 87.1, 3-y: 54.1, 5-y: 49.2 | ||
| Chen | LG | 19 (1–48) | NR | NR | 1-y: 91.5 |
| OG | NR | NR | 1-y: 89.8 | ||
| Chun | LG | 53.2 (1–82.2) | 4 | NR | 5-y: 91.3 |
| OG | 60.4 (7–91.7) | 7 | NR | 5-y: 88.6 | |
| Kim | LG | 53.7 (8.3−138.1) | 13 | 5-y: 84.6 | 5-y: 85.9 |
| OG | 58.1 (0.3−106.2) | 15 | 5-y: 81.1 | 5-y: 83.1 | |
| Moisan | LG | 28 | 5 | 3-y: 79.4 | 3-y: 82.3 |
| OG | 40 | 4 | 3-y: 83.4 | 3-y: 86.9 | |
| Siani | LG | 32.6 | NR | 5-y: 54.2 | 5-y: 55.7 |
| OG | 31.9 | NR | 5-y: 52.1 | 5-y: 52.9 | |
| Shinohara | LG | 48.8 (25–58.5)a | 53 | 5-y: 65.8b | 5-y: 68.1b |
| OG | 34 | 5-y: 62.0b | 5-y: 63.7b |
Abbreviations: DFS Disease-free survival, OS Overall survival, y Year, NR Not reported.
Follow-up time are shown as median (range); ashown as interquartile range; bcalculated by excluding stage IA and missing follow-up patients.